OncoSil Medical Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de OncoSil Medical.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Life Sciences	18.5%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?

Dec 04

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como OncoSil Medical no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

ASX:OSL - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2023	1	-12	-10	-10	N/A
9/30/2023	1	-12	-11	-11	N/A
6/30/2023	1	-11	-11	-11	N/A
3/31/2023	1	-11	-11	-11	N/A
12/31/2022	1	-11	-10	-10	N/A
9/30/2022	1	-11	-10	-10	N/A
6/30/2022	1	-11	-10	-10	N/A
3/31/2022	1	-11	-11	-11	N/A
12/31/2021	1	-11	-11	-11	N/A
9/30/2021	1	-11	-10	-10	N/A
6/30/2021	1	-10	-9	-9	N/A
3/31/2021	2	-8	-8	-8	N/A
12/31/2020	2	-6	-7	-7	N/A
9/30/2020	2	-5	-6	-6	N/A
6/30/2020	3	-4	-4	-4	N/A
3/31/2020	3	-6	-5	-5	N/A
12/31/2019	3	-7	-6	-6	N/A
9/30/2019	3	-8	-7	-7	N/A
6/30/2019	4	-9	-8	-8	N/A
3/31/2019	4	-9	-8	-8	N/A
12/31/2018	4	-9	-8	-8	N/A
9/30/2018	4	-9	-8	-8	N/A
6/30/2018	4	-9	-8	-8	N/A
3/31/2018	4	-8	-8	-8	N/A
12/31/2017	4	-8	-7	-7	N/A
9/30/2017	4	-8	N/A	-7	N/A
6/30/2017	4	-7	N/A	-6	N/A
3/31/2017	3	-7	N/A	-6	N/A
12/31/2016	2	-6	N/A	-5	N/A
9/30/2016	3	-5	N/A	-5	N/A
6/30/2016	4	-5	N/A	-5	N/A
3/31/2016	4	-3	N/A	-3	N/A
12/31/2015	4	-2	N/A	-1	N/A
9/30/2015	3	-3	N/A	0	N/A
6/30/2015	3	-3	N/A	0	N/A
3/31/2015	2	-5	N/A	N/A	N/A
12/31/2014	2	-7	N/A	-5	N/A
9/30/2014	1	-7	N/A	-6	N/A
6/30/2014	0	-7	N/A	-6	N/A
3/31/2014	0	-5	N/A	N/A	N/A
12/31/2013	N/A	-3	N/A	-2	N/A
9/30/2013	N/A	-2	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de OSL es superior a la tasa de ahorro (2.2%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de OSL crezcan más rápidamente que el mercado Australian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de OSL crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de OSL crezcan más rápidamente que el mercado de Australian.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de OSL crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de OSL se prevé que sea elevada dentro de 3 años.

OncoSil Medical Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Price target increased to AU$0.17

Analysts lower revenue estimates to AU$189.0k

Price target lowered to AU$0.34

Analysts update estimates

Recent updates

OncoSil Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 1.48 million.

New major risk - Market cap size

Oncosil Medical Limited Elects Gabrielle Liberatore as Director

New major risk - Market cap size

New major risk - Share price stability

OncoSil Medical Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.013 loss in FY 2022)

OncoSil Appoints Gabriel Liberatore to the Board

OncoSil Medical Limited Announces Appointment of Dal Cin as Chief Financial Officer

Oncosil Medical Ltd Announces Resignation of Karl Pechmann as Chief Financial Officer

Insider recently bought AU$1.2m worth of stock

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.007 loss in 1H 2022)

Oncosil Medical Limited Announces Two Key Treatment Centres Treat First Patients with Oncosil

OncoSil Medical Limited has completed a Follow-on Equity Offering in the amount of AUD 6.09495 million.

Forecast to breakeven in 2025

Less than half of directors are independent

OncoSil Medical Limited Announces Resignation of Martin Cross as Director

OncoSil Medical Ltd Appoints Brian Leedman to the Board as a Non-Executive Director

Forecast to breakeven in 2025

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

OncoSil Medical Limited, Annual General Meeting, Oct 25, 2022

Oncosil Medical Ltd Announces Second Patient Treated in Spain Proceeds to Successful Resection

Companies Like OncoSil Medical (ASX:OSL) Could Be Quite Risky

Less than half of directors are independent

OncoSil Medical Ltd. Announces the First Commercial Treatment of the OncoSilTM Device in Europe

OncoSil Medical Limited Announces Fully-Funded Trial Approval in Germany To Increase Sales of OncoSil Device

Price target increased to AU$0.17

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're Watching OncoSil Medical's (ASX:OSL) Cash Burn Situation

Oncosil Medical Limited announces PanCO Clinical Study on OncoSil(TM) Published in ESMO Open

Less than half of directors are independent

Is OncoSil Medical (ASX:OSL) In A Good Position To Deliver On Growth Plans?

Full year 2021 earnings released: AU$0.013 loss per share (vs AU$0.006 loss in FY 2020)

OncoSil Medical Limited Provides Update on TGA Regulatory

OncoSil Medical (ASX:OSL) Is In A Good Position To Deliver On Growth Plans

OncoSil Medical's (ASX:OSL) Stock Price Has Reduced 42% In The Past Five Years

Analysts lower revenue estimates to AU$189.0k

Price target lowered to AU$0.34

First half 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in 1H 2020)

OncoSil Medical Limited Announces Executive Appointments

We're Not Worried About OncoSil Medical's (ASX:OSL) Cash Burn

OncoSil Medical Limited Appoints Nigel Lange as Chief Executive Officer

How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?

OncoSil Medical Limited Announces Executive Changes

OncoSil Medical Limited Receives Swiss Regulatory Approval

Independent Non-Executive Chairman recently bought AU$405k worth of stock

Analysts update estimates

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento